eNewsroom for: Empire Genomics

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Empire Genomics/Screen Shot 2012-11-28 at 6.33.17 PM.png

Empire Genomics Company Profile

Empire Genomics was created in 2006 from research started at the prestigious Roswell Park Cancer Institute in Buffalo, New York. The laboratory has a strong track record in the development of high throughput technologies to enable genome-wide analyses aimed at determining the underlying mechanisms for diseases. Having played a fundamental role in the Human Genome Project and created the foundational Bacterial Artificial Chromosomes which served as the basis for sequencing the genome, Empire Genomics developed significant expertise in genomic research. It is from this strong experiential base that we bring our capabilities, tools and techniques to support the research, clinical and drug discovery global community.

News from Empire Genomics:

New York State Department of Health Issues Clinical Laboratory Permit to Empire Genomics

Molecular diagnostics company launches for full-service CLIA LDT menu
BUFFALO, N.Y., Nov. 12, 2013 /PRNewswire/ — Empire Genomics, LLC (www.empiregenomics.com), an emerging molecular diagnostics company in the field of personalized medicine, announced today that its clinical laborator…

Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma

Company Plans to Allocate Funds for Investigation into Methods in Genomics to Predict Multiple Myeloma Patient Response to Therapeutic Treatments
BUFFALO, N.Y., May 28, 2013 /PRNewswire/ – Empire Genomics, LLC (www.empiregenomics.com) has been awarded a Phase I SBIR Grant by the National…

Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer

Exciting new precision medicine tool for diagnosing and guiding treatment of patients with NEPC Prostate Cancer
BUFFALO, N.Y., May 22, 2013 /PRNewswire/ – Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell Univers…

Empire Genomics Licenses First Known DNA Biomarker for Use in Determining Drug Response in Multiple Myeloma and Potentially Lymphoma Patients

Detection of Gene Abnormalities May Help Patients and Physicians Determine the Best Approach to Treatment, Improve Survival Rate and Lower Treatment Costs
BUFFALO, N.Y., Nov. 29, 2012 /PRNewswire/ — Empire Genomics announced today it has acquired an exclusive license for patent pending nove…